iShares China Large-Cap ETF vs Rocket Lab USA Inc — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while Rocket Lab USA Inc trades at $68.21 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 11.3× iShares China Large-Cap ETF's market cap, and Rocket Lab USA Inc is more actively traded (22,892,581 versus 16,323,837). Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Rocket Lab USA Inc for 29 Days on average.
| FXI | RKLB | |
|---|---|---|
Market Cap | $3.86B | $43.74B |
Volume | 16,323,837 | 22,892,581 |
52-Week High | $41.08 | $150.23 |
52-Week Low | $31.59 | $39.48 |
Typical Hold Time | 150 Days | 29 Days |
Sector | — | Industrials |
Enterprise Value | — | $41.57B |
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting cautious sentiment amid mixed technical signals. The ETF shows bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions, while corporate profits showed strong growth in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E ratio approximately half that of the S&P 500.
FXI offers value exposure to Chinese large-caps but faces headwinds from geopolitical risks and economic rebalancing. The Trump-Xi summit provided limited progress on trade tensions, while China's export controls and domestic stimulus measures create uncertainty. Institutional sentiment remains divided between the valuation opportunity and persistent political risks.
Rocket Lab (RKLB) trades at $68.40, down 4.89% today, amid bearish technical signals despite positive business developments. The company recently secured its largest-ever commercial Electron launch contract with Synspective for 20 missions, expanding its backlog to over 100 launches. Fundamentally, RKLB shows strong revenue growth with $602 million in 2025 and projected $769 million in 2026, though it remains unprofitable with negative margins. Analyst sentiment remains overwhelmingly bullish with 16 buy ratings and a $107 consensus price target, representing significant upside potential from current levels.
Rocket Lab presents a high-risk, high-reward opportunity with substantial growth potential in the expanding space economy offset by persistent losses and competitive threats from SpaceX. The company's expanding launch backlog and Neutron rocket development provide long-term catalysts, but investors must weigh the premium valuation against ongoing cash burn and execution risks in a capital-intensive industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →